BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109:914-922. [PMID: 25956020 DOI: 10.1016/j.rmed.2015.04.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Hume E, Ward L, Wilkinson M, Manifield J, Clark S, Vogiatzis I. Exercise training for lung transplant candidates and recipients: a systematic review. Eur Respir Rev 2020;29:200053. [PMID: 33115788 DOI: 10.1183/16000617.0053-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nunes FS, Pastre J, Brown AW, Shlobin OA, King C, Weir NA, Nathan SD. Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis? Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021005. [PMID: 33867792 DOI: 10.36141/svdld.v38i1.9258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Machado FVC, Bloem AEM, Schneeberger T, Jarosch I, Gloeckl R, Winterkamp S, Franssen FME, Koczulla AR, Pitta F, Spruit MA, Kenn K. Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis. BMJ Open Respir Res 2021;8:e001039. [PMID: 34711642 DOI: 10.1136/bmjresp-2021-001039] [Reference Citation Analysis]
4 Delanote I, Wuyts WA, Yserbyt J, Verbeken EK, Verleden GM, Vos R. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med 2016;16:156. [PMID: 27863518 DOI: 10.1186/s12890-016-0308-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
5 Spagnolo P, Cocconcelli E, Cottin V. Clinical Trials in IPF: What Are the Best Endpoints? In: Meyer KC, Nathan SD, editors. Idiopathic Pulmonary Fibrosis. Cham: Springer International Publishing; 2019. pp. 433-53. [DOI: 10.1007/978-3-319-99975-3_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Case AH, Hellkamp AS, Neely ML, Bender S, Dilling DF, Gulati M, Hotchkin DL, Huie TJ, Lancaster L, Snyder LD, Conoscenti CS, Palmer SM. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry. Ann Am Thorac Soc 2020;17:699-705. [PMID: 32040340 DOI: 10.1513/AnnalsATS.201906-437OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
7 Hirabayashi R, Takahashi Y, Nagata K, Morimoto T, Wakata K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K. The validity and reliability of four-meter gait speed test for stable interstitial lung disease patients: the prospective study. J Thorac Dis 2020;12:1296-304. [PMID: 32395266 DOI: 10.21037/jtd.2020.02.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Zhang Y, Gu L, Xia Q, Tian L, Qi J, Cao M. Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis. Front Pharmacol 2020;11:415. [PMID: 32425767 DOI: 10.3389/fphar.2020.00415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Matsuo S, Okamoto M, Ikeuchi T, Zaizen Y, Inomoto A, Haraguchi R, Mori S, Sasaki R, Nouno T, Tanaka T, Hoshino T, Tsuda T. Early Intervention of Pulmonary Rehabilitation for Fibrotic Interstitial Lung Disease Is a Favorable Factor for Short-Term Improvement in Health-Related Quality of Life. J Clin Med 2021;10:3153. [PMID: 34300319 DOI: 10.3390/jcm10143153] [Reference Citation Analysis]
10 Tony FA, Soliman YMA, Salem HA. Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis. J Asthma Allergy 2021;14:501-11. [PMID: 34007188 DOI: 10.2147/JAA.S299939] [Reference Citation Analysis]
11 Baddini-Martinez JA. Six-minute walk test in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2018;44:257-8. [PMID: 30328922 DOI: 10.1590/S1806-37562018000040001] [Reference Citation Analysis]
12 Pople J. Palliative care for people living with end-stage pulmonary disease. Int J Palliat Nurs 2017;23:486-95. [PMID: 29087752 DOI: 10.12968/ijpn.2017.23.10.486] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Robbie H, Daccord C, Chua F, Devaraj A. Evaluating disease severity in idiopathic pulmonary fibrosis. Eur Respir Rev 2017;26:170051. [PMID: 28877976 DOI: 10.1183/16000617.0051-2017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
14 Kaleth AS, Slaven JE, Ang DC. Determining the Minimal Clinically Important Difference for 6-Minute Walk Distance in Fibromyalgia. Am J Phys Med Rehabil 2016;95:738-45. [PMID: 27003201 DOI: 10.1097/PHM.0000000000000485] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
15 Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur Respir Rev 2020;29:200154. [PMID: 33153990 DOI: 10.1183/16000617.0154-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Agarwala P, Salzman SH. Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement. Chest 2020;157:603-11. [PMID: 31689414 DOI: 10.1016/j.chest.2019.10.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
17 Meyer KC. Pulmonary fibrosis, part II: state-of-the-art patient management. Expert Rev Respir Med 2017;11:361-76. [PMID: 28345369 DOI: 10.1080/17476348.2017.1312347] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. Pharmacoeconomics 2018;36:779-807. [PMID: 29492843 DOI: 10.1007/s40273-018-0631-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
19 Denzer-Weiler C, Hreha K. The use of animal-assisted therapy in combination with physical therapy in an inpatient rehabilitation facility: A case report. Complement Ther Clin Pract 2018;32:139-44. [PMID: 30057041 DOI: 10.1016/j.ctcp.2018.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Kang M, Veeraraghavan S, Martin GS, Kempker JA. An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis. ERJ Open Res 2021;7:00142-2021. [PMID: 34671666 DOI: 10.1183/23120541.00142-2021] [Reference Citation Analysis]
21 Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res 2019;20:205. [PMID: 31492155 DOI: 10.1186/s12931-019-1161-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 18.7] [Reference Citation Analysis]
22 Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine 2019;40:554-63. [PMID: 30616998 DOI: 10.1016/j.ebiom.2018.12.052] [Cited by in Crossref: 324] [Cited by in F6Publishing: 302] [Article Influence: 108.0] [Reference Citation Analysis]
23 Fernández Fabrellas E, Peris Sánchez R, Sabater Abad C, Juan Samper G. Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis. Med Sci (Basel) 2018;6:E51. [PMID: 29904028 DOI: 10.3390/medsci6020051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
24 Brown AW, Nathan SD. The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. Annals ATS 2018;15:3-10. [DOI: 10.1513/annalsats.201703-244fr] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
25 Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, Bouros D, Glassberg MK. Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2018;5:142. [PMID: 29868594 DOI: 10.3389/fmed.2018.00142] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
26 Mancuzo EV, Soares MR, Pereira CAC. Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil. J Bras Pneumol 2018;44:267-72. [PMID: 30328926 DOI: 10.1590/S1806-37562018000000049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Phillips D, Tomazos IC, Moseley S, L'Italien G, Gomes da Silva H, Lerma Lara S. Reliability and Validity of the 6-Minute Walk Test in Hypophosphatasia. JBMR Plus 2019;3:e10131. [PMID: 31346563 DOI: 10.1002/jbm4.10131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
28 Sato T, Sato S, Oshima Y, Yoshioka Y, Hamada R, Nankaku M, Ikeda M, Nakajima D, Chen-Yoshikawa TF, Date H, Matsuda S, Tabira K. Impact of inspiratory muscle strength on exercise capacity after lung transplantation. Physiother Res Int 2022;:e1951. [PMID: 35396918 DOI: 10.1002/pri.1951] [Reference Citation Analysis]
29 Choi W. Current and future treatment for idiopathic pulmonary fibrosis. J Korean Med Assoc 2021;64:256-63. [DOI: 10.5124/jkma.2021.64.4.256] [Reference Citation Analysis]
30 Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016;48:843-51. [DOI: 10.1183/13993003.01966-2015] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 13.5] [Reference Citation Analysis]
31 Kang M, Marts L, Kempker JA, Veeraraghavan S. Minimal clinically important difference in idiopathic pulmonary fibrosis. Breathe (Sheff) 2021;17:200345. [PMID: 34295421 DOI: 10.1183/20734735.0345-2020] [Reference Citation Analysis]
32 Lancaster L, Fieuw A, Meulemans J, Ford P, Nathan SD. Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. Contemp Clin Trials 2021;100:106227. [PMID: 33246099 DOI: 10.1016/j.cct.2020.106227] [Reference Citation Analysis]
33 Lancaster LH. Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2018;13:45. [PMID: 30559965 DOI: 10.1186/s40248-018-0158-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
34 Lancaster L, Goldin J, Trampisch M, Kim GH, Ilowite J, Homik L, Hotchkin DL, Kaye M, Ryerson CJ, Mogulkoc N, Conoscenti CS. Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respir Med J 2020;14:22-31. [PMID: 33088361 DOI: 10.2174/1874306402014010022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail 2017;19:718-27. [PMID: 28345190 DOI: 10.1002/ejhf.809] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
36 Puxeddu E, Rogliani P. Prognostic scoring systems for clinical course and survival in idiopathic pulmonary fibrosis. World J Respirol 2016; 6(1): 14-23 [DOI: 10.5320/wjr.v6.i1.14] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Keeratichananont W, Thanadetsuntorn C, Keeratichananont S. Value of preoperative 6-minute walk test for predicting postoperative pulmonary complications. Ther Adv Respir Dis 2016;10:18-25. [PMID: 26546478 DOI: 10.1177/1753465815615509] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
38 Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A. Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respir Res 2019;20:47. [PMID: 30823880 DOI: 10.1186/s12931-019-1010-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
39 Ntolios P, Manoloudi E, Tzouvelekis A, Bouros E, Steiropoulos P, Anevlavis S, Bouros D, Froudarakis ME. Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Clin Respir J. 2018;12:2084-2089. [PMID: 29412521 DOI: 10.1111/crj.12777] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
40 Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Lake F, Hopkins PMA, Corte TJ, Allan H, Glaspole IN. The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology 2017;22:1459-72. [PMID: 28891101 DOI: 10.1111/resp.13163] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
41 Hsu YT, Turner K, Lee SP. Post-acute physical therapy for a patient with critical illness associated with COVID-19: A case report. Physiother Theory Pract 2021;:1-7. [PMID: 34455906 DOI: 10.1080/09593985.2021.1972499] [Reference Citation Analysis]